Search Results - "Warzocha, K."

FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism by Sewastianik, T, Szydlowski, M, Jablonska, E, Bialopiotrowicz, E, Kiliszek, P, Gorniak, P, Polak, A, Prochorec-Sobieszek, M, Szumera-Cieckiewicz, A, Kaminski, T S, Markowicz, S, Nowak, E, Grygorowicz, M A, Warzocha, K, Juszczynski, P

“…Molecular profiling has led to identification of subtypes of diffuse large B-cell lymphomas (DLBCLs) differing in terms of oncogenic signaling and metabolic…”
Get full text

The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant by NASILOWSKA-ADAMSKA, B, RZEPECKI, P, DUDA, D, SZYDLO, R, HALABURDA, K, SZCZEPINSKI, A, LANGE, A, HELLMAN, A, ROBAK, T, SKOTNICKI, A, JEDRZEJCZAK, W. W, WALEWSKI, J, MANKO, J, HOLOWIECKI, J, KOMARNICKI, M, DMOSZYNSKA, A, WARZOCHA, K, MARIANSKA, B, CZYZ, A, MARKIEWICZ, M, FEDEROWICZ, I, TOMASZEWSKA, A, PIATKOWSKA-JAKUBAS, B, WRZESIEN-KUS, A, BIENIASZEWSKA, M

“…In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and…”
Get full text

OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8) by Paszkiewicz‐Kozik, E., Michalski, W., Taszner, M., Knopińska‐Posłuszny, W., Mordak‐Domagała, M., Najda, J., Borawska, A., Romejko‐Jarosińska, J., Chełstowska, M., Świerkowska, M., Dąbrowska‐Iwanicka, A., Malenda, A., Druzd‐Sitek, A., Konecki, R., Kuniega, B., Osowiecki, M., Ostrowska, B., Szpila, T., Domańska‐Czyż, K., Szymański, M., Targoński, Ł., Poplawska, L., Kotarska, M., Giebel, S., Lange, A., Pluta, A., Warzocha, K., Zaucha, J., Rymkiewicz, G., Walewski, J.

Get full text

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) by Kalakonda, N., Cavallo, F., Follows, G., Goy, A., Vermaat, J., Casasnovas, O., Lavee, O., Maerevoet, M., Zijlstra, J., Bakshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J., Schuster, M., Thieblemont, C., De la Cruz, F., Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T., Warzocha, K., Oluyadi, A., McCarthy, D., Ma, X., Corona, K., Shah, J., Van Den Neste, E., Canales, M.

Get full text

EXPRESSION OF PIM KINASES IN REED‐STERNBERG CELLS FOSTERS IMMUNE PRIVILEGE AND TUMOR CELL SURVIVAL IN HODGKIN LYMPHOMA by Szydlowski, M., Prochorec‐Sobieszek, M., Szumera‐Ciećkiewicz, A., Derezińska, E., Hoser, G., Wasilewska, D., Szymańska‐Giemza, O., Jabłońska, E., Białopiotrowicz, E., Sewastianik, T., Polak, A., Czardybon, W., Gałęzowski, M., Windak, R., Zaucha, J., Warzocha, K., Brzózka, K., Juszczyński, P.

Get full text

Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients by Warzocha, K, Salles, G, Bienvenu, J, Bastion, Y, Dumontet, C, Renard, N, Neidhardt-Berard, E M, Coiffier, B

“…A prospective study was performed to assess plasma measurement of tumor necrosis factor (TNF), lymphotoxin alpha (LTalpha), and their soluble receptors (p55…”
Get more information

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients by Czyż, J., Dziadziuszko, R., Knopińska-Postuszuy, W., Hellmann, A., Kachel, Ł., Hołowiecki, J., Goździk, J., Hansz, J., Avigdor, A., Nagler, A., Osowiecki, M., Walewski, J., Mensah, P., Jurczak, W., Skotnicki, A., Sędzimirska, M., Lange, A., Sawicki, W., Sułek, K., Wach, M., Dmoszyńska, A., Kuś, A., Robak, T., Warzocha, K.

“…Background: The reported probability of survival of patients with Hodgkin's disease (HD) following high-dose chemotherapy with autologous stem cell…”
Get full text

Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2‐CdA): an unusual variant of Richter's syndrome by Robak, T., Urbańska‐Ryś, H., Strzelecka, B., Krykowski, E., Bartkowiak, J., Boński, J. Z., Kordek, R., Warzocha, K.

“…: Patients with chronic lymphocytic leukemia (CLL) may develop a large‐cell transformation known as Richter's syndrome (RS). RS usually presents as diffuse…”
Get full text

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients by WARZOCHA, K, BIENVENU, J, RIBEIRO, P, MOULLET, I, DUMONTET, C, NEIDHARDT-BERARD, E. M, COIFFIER, B, SALLES, G

“…A prospective study was performed to assess the use of plasma measurement of tumour necrosis factor (TNF), lymphotoxin alpha (LT alpha) and their soluble…”
Get full text

Diagnostic and therapeutic quandaries in primary manifestation of Hodgkin's disease in the central nervous system by KALINKA, E, ROBAK, T, WRZESIEN-KUS, A, KRYKOWSKI, E, WARZOCHA, K

“…We report the case of a 23-year-old female with severe neurologic dysfunction without a clear cause at the time of initial presentation. The search for an…”
Get full text

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group by CZYZ, J, HELLMANN, A, MEDER, J, WALEWSKI, J, LAMPKA, E, SUŁEK, K, SAWICKI, W, LANGE, A, FORGACZ, K, SUCHNICKI, K, PACUSZKO, T, SKOTNICKI, A, DZIADZIUSZKO, R, MENSAH, P, JURCZAK, W, KULICZKOWSKI, K, WROBEL, T, MAZUR, G, DMOSZYNSKA, A, WACH, M, ROBAK, T, WARZOCHA, K, HANSZ, J, GOZDZIK, J, HOŁOWIECKI, J, STELLA-HOŁOWIECKA, B, KACHEL, Ł, KNOPINSKA-POSŁUSZNY, W, NAGLER, A

“…We analysed the treatment outcome of primary refractory HD patients managed with high-dose chemotherapy and haematopoietic cell transplantation. Data of 65…”
Get full text

2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia by Warzocha, K., Fabianowska-Majewska, K., Bloński, J., Krykowski, E., Robak, T.

Get full text

Leczenie chorych na chłoniaki rozlane z dużych komórek B by Warzocha, K.

Get full text

Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study by Walewski, J, Kraszewska, E, Mioduszewska, O, Romejko-Jarosińska, J, Hellmann, A, Czyz, J, Hołowiecki, J, Kopera, M, Grosicki, S, Komarnicki, M, Rumianowski, L, Kuliczkowski, K, Wróbel, T, Dwilewicz-Trojaczek, J, Robak, T, Warzocha, K, Załuski, J, Wójcik, E, Dmoszyńska, A, Walter-Croneck, A

“…The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses in patients with recurrent…”
Get full text

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib by Gullaksen, Stein-Erik, Skavland, Jørn, Gavasso, Sonia, Tosevski, Vinko, Warzocha, Krzysztof, Dumrese, Claudia, Ferrant, Augustin, Gedde-Dahl, Tobias, Hellmann, Andrzej, Janssen, Jeroen, Labar, Boris, Lang, Alois, Majeed, Waleed, Mihaylov, Georgi, Stentoft, Jesper, Stenke, Leif, Thaler, Josef, Thielen, Noortje, Verhoef, Gregor, Voglova, Jaroslava, Ossenkoppele, Gert, Hochhaus, Andreas, Hjorth-Hansen, Henrik, Mustjoki, Satu, Sopper, Sieghart, Giles, Francis, Porkka, Kimmo, Wolf, Dominik, Gjertsen, Bjørn Tore

“…Monitoring of single cell signal transduction in leukemic cellular subsets has been proposed to provide deeper understanding of disease biology and prognosis,…”
Get full text

PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor by Casasnovas, R.O., Daniele, P., Tremblay, G., Maerevoet, M., Zijlstra, J., Follows, G., Vermaat, J.S.P., Kalakonda, N., Goy, A.H., Choquet, S., Van Den Neste, E., Hill, B.T., Thieblemont, C., Cavallo, F., de la Cruz, F., Kuruvilla, J., Hamad, N., Bouabdallah, R., Jäger, U., Caimi, P., Gurion, R., Warzocha, K., Bakhshi, S., Sancho, J.M., Schuster, M., Egyed, M., Offner, F., Vasilakopoulos, T., Samal, P., Nagy, A., Ku, M., Canales Albendea, M.Á.

Get full text

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma by Lech-Maranda, Ewa, Baseggio, Lucile, Bienvenu, Jacques, Charlot, Carole, Berger, Françoise, Rigal, Dominique, Warzocha, Krzysztof, Coiffier, Bertrand, Salles, Gilles

“…The aim of the study was to investigate whether interleukin-10 (IL-10) genetic polymorphisms influence this cytokine production as well as the incidence and…”
Get full text

The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor-α or its mutein on murine leukaemias L1210 and P388 by Góra-Tybor, J., Warzocha, K., Robak, T.

“…WE investigated the influence of 2-chlorodeoxyadenosine (2-CdA) in combination with tumour necrosis factor-α (TNFα) or its mutein VI, which differs from the…”
Get full text

IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation by Jaskula, E., Lange, A., Dlubek, D., Kyrcz-Krzemień, S., Markiewicz, M., Dzierzak-Mietla, M., Jedrzejczak, W. W., Gronkowska, A., Nowak, J., Warzocha, K., Hellmann, A., Kowalczyk, J., Drabko, K., Goździk, J., Mizia, S.

“…Four hundred and ninety‐five patients (390 and 105 grafted from unrelated and sibling (SIB) donors, respectively) and their donors were analyzed for the impact…”
Get full text

Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma by Warzocha, K, Krykowksi, E, Góra-Tybor, J, Fronczak, A, Robak, T

“…2-chlorodeoxyadenosine (2-CdA) has been demonstrated to be a neurotoxic agent when used at significantly greater doses than currently recommended for clinical…”
Get more information